Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Coronary Disease × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 8 Other 5 Gynecologic 2 Gastrointestinal 2 Thoracic 1 Lymphoid 1 Endocrine 1

Conditions

Neuroendocrine Tumors 484 Multiple Endocrine Neoplasia Type 1 174 Pituitary Neoplasms 166 Thyroid Cancer, Papillary 152 Pheochromocytoma 134 Carcinoma, Neuroendocrine 124 Thyroid Neoplasms 110 Neoplasms 98 Paraganglioma 85 Carcinoid Tumor 85 Adrenocortical Carcinoma 79 Thyroid Carcinoma, Anaplastic 71 Pancreatic Neoplasms 62 Neoplasm Metastasis 57 Insulinoma 57 Adrenal Gland Neoplasms 57 Carcinoma, Medullary 54 Gastro-enteropancreatic neuroendocrine tumor 53 Carcinoma, Non-Small-Cell Lung 52 Adenoma, Islet Cell 52 Breast Neoplasms 50 Colorectal Neoplasms 46 Adenocarcinoma, Follicular 46 Lung Neoplasms 42 Sarcoma 41 Prostatic Neoplasms 41 Melanoma 41 Carcinoma, Renal Cell 41 Carcinoma, Hepatocellular 41 Small Cell Lung Carcinoma 40

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03872401 2025-11-10

VESALIUS-CV

Amgen

Phase 3 Completed

12,301 enrolled

Coronary Disease, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡